

# 1 week to go to SMI's 22nd Annual Superbugs & Superdrugs Conference

*SMi Reports: Superbugs & Superdrugs conference taking place next week, will now be by remote access only*

LONDON, UNITED KINGDOM, March 24, 2020 /EINPresswire.com/ -- With only 1 week remaining, the 22nd Annual Superbugs & Superdrugs Conference will reconvene on the [30 and 31 March, with remote access only](#). This year's global focused two-day conference pharmaceutical is for industry professionals looking to gain an in-depth knowledge of the scientific, economic, and regulatory challenges facing the critical global issue of antibiotic resistance.

Interested parties are urged to register at: [www.superbugssuperdrugs.com/einPR6](http://www.superbugssuperdrugs.com/einPR6)

The conference will consist of an impressive [15+ speaker line-up from well-established big pharma, academia and government organisations](#), where delegates can hear their extensive experiences and knowledge on the critical subject of growing antibiotic resistance.

The two-day conference is co-chaired by Cara Cassino, CMO, Contrafect and Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy.

## [Featured 2020 Experts and Remote Presentations:](#)

Exploring new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins  
Yuri Gleba, Professor, Founder, Nomad Bioscience

Update on the UK project looking at novel value assessment and reimbursement for novel antimicrobials  
Colm Leonard, Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Professor of Medicine, NICE & Manchester University NHS Foundation Trust

The BARDA Antibacterials Program  
Brian Tse, Health Scientist, Biomedical Advanced Research and Development Authority (BARDA)



SMi's 22nd Annual Conference on... 

# Superbugs & Superdrugs

30-31 March 2020 | REMOTE ACCESS ONLY

Understanding the scientific, regulatory and economic challenges required to combat anti-microbial resistance

[www.superbugssuperdrugs.com](http://www.superbugssuperdrugs.com)  
#smibugs

superbugs 2020 remote

Discovery of Dabocins, a novel class of non- $\beta$ -lactam PBP inhibitors  
Francois Moreau, Scientific Director, Mutabilis S A  
Evaluating the utility of machine learning and AI in antibiotic drug discovery  
Paul Finn, CEO, Oxford Drug Design

The conference with remote access is available for registration for only £999. Register at [www.superbugssuperdrugs.com/einPR6](http://www.superbugssuperdrugs.com/einPR6)

The event is sponsored by Scynexis.  
For sponsorship enquiries, contact Alia Malick on +44 (0)20 7827 6164 or [amalick@smi-online.co.uk](mailto:amalick@smi-online.co.uk)

For registration information, contact Dylan Brohm at [dbrohm@smi-online.co.uk](mailto:dbrohm@smi-online.co.uk) or call on +44 (0) 207 827 1024.

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or [ssapal@smi-online.co.uk](mailto:ssapal@smi-online.co.uk)

Superbugs & Superdrugs 2020  
Conference: 30th – 31st March 2020  
Remote Access Only  
[www.superbugssuperdrugs.com/einPR6](http://www.superbugssuperdrugs.com/einPR6)  
#SMiBugs

--- ENDS –

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Simi Sapal  
SMi Group  
+442078276000  
[email us here](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.  
© 1995-2020 IPD Group, Inc. All Right Reserved.